Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4223 US real-world study of the burden of medication in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Patients with NETs experience a range of comorbidities, and often present with carcinoid syndrome (CS).

Conference:

Presenting Author:

Authors: Chan J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Starr J,

Keywords: gastroenteropancreatic, neuroendocrine tumor, concomitant medication, burden,

#4190 Burden of medication in patients with lung neuroendocrine tumors (NETs) in a US real-world setting

Introduction: Real-world evidence on patients with lung NETs, specifically on comorbidities and the prevalence of carcinoid syndrome (CS), is lacking.

Conference:

Presenting Author:

Authors: Starr J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Chan J,

Keywords: lung, neuroendocrine tumor, concomitant medication, costs,

#3335 Efficacy of somatostatin analogue (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)

Introduction: Currently, there is minimal published data on the efficacy of SSAs for well-differentiated G3 NETs. Randomized trials have demonstrated a progression-free survival (PFS) benefit and limited response for lower grade 1-2 NETs, but the optimal therapy for metastatic G3 NETs is unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: McGarrah P

Authors: McGarrah P, Liu A, Hobday T, Starr J, Kendi A,

Keywords: somatostatin analogues, lanreotide, octreotide, well-differentiated grade 3 neuroendocrine tumor, G3net, G3nen,

#3254 COVID-19 in patients with neuroendocrine tumors (NETs): The Mayo Clinic experience

Introduction: Coronavirus Disease 2019 (COVID-19) has been associated with increased morbidity and mortality in cancer patients. NETs are rare and there is paucity of data about COVID-19 outcomes.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Rakshit S

Authors: Rakshit S, Lee K, Kendi A, Sonbol M, Starr J,

Keywords: neuroendocrine tumor, covid-19, outcomes, mortality,

#3012 Causes of Death Following Neuroendocrine Tumors Diagnosis: A United States Population-Based Analysis

Introduction: Neuroendocrine tumors (NET) are heterogeneous in terms of prognosis based on location, grade, and stage.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sonbol M

Authors: Saad A, Halfdanarson T, Starr J, Sonbol M,

Keywords: neuroendocrine tumors, survivorship, non-cancer causes of death,